JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase 3

Active, not recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: Ustekinumab Dose Based on BSA and Body Weight
Drug: Matching Placebo

First Posted Date: 2020-11-16

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 112

Registration Number: NCT04630028

Locations: 🇮🇱
Shamir Medical Center Assaf Harofeh, Be Er Ya Akov, Israel
🇺🇸
Nemours DuPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸
Children's Center for Digestive Health Care, Atlanta, Georgia, United States

and more 55 locations

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

Phase 2

Active, not recruiting

Conditions: Alzheimer Disease
Cognitive Dysfunction
Dementia

Interventions: Drug: JNJ-63733657
Drug: Placebo

First Posted Date: 2020-11-06

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 523

Registration Number: NCT04619420

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Dignity Health, Phoenix, Arizona, United States
🇺🇸
Irvine Clinical Research, Irvine, California, United States

and more 118 locations

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Guselkumab

First Posted Date: 2020-11-05

Last Posted Date: 2021-08-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 140

Registration Number: NCT04617691

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: JNJ-42847922

First Posted Date: 2020-11-05

Last Posted Date: 2023-02-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT04616677

Locations: 🇺🇸
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Benlysta
Drug: Candin

First Posted Date: 2020-11-02

Last Posted Date: 2021-06-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 13

Registration Number: NCT04611971

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes

Interventions: Drug: JNJ-74856665
Drug: VEN
Drug: AZA

First Posted Date: 2020-10-30

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 153

Registration Number: NCT04609826

Locations: 🇫🇷
Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac, France
🇫🇷
CHU de Nice Hopital de l Archet, Nice, France
🇫🇷
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse cedex 09, France

and more 17 locations

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

Phase 1

Active, not recruiting

Conditions: Advanced Solid Malignancies

Interventions: Drug: Ami-LC-MD
Drug: Ami-HC
Drug: Ami-HC-CF
Drug: Ami-LC
Drug: Lazertinib

First Posted Date: 2020-10-28

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 159

Registration Number: NCT04606381

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇺🇸
Community Health Network, Indianapolis, Indiana, United States
🇬🇧
Royal Marsden Hospital, Sutton, United Kingdom

and more 9 locations

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Conditions: Metastatic Non-Small Cell Lung Cancer

First Posted Date: 2020-10-23

Last Posted Date: 2021-06-29

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04599712

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Phase 4

Completed

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Esketamine 84 mg
Drug: Placebo
Drug: Esketamine 56 mg

First Posted Date: 2020-10-23

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 477

Registration Number: NCT04599855

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States

and more 50 locations

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cosentyx
Drug: Candin

First Posted Date: 2020-10-19

Last Posted Date: 2021-06-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT04589026

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy